|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Searle_Pharmaceuticals
|
|
gptkbp:activities
|
GABA receptor agonist
|
|
gptkbp:appointed_by
|
oral solution
|
|
gptkbp:approves
|
gptkb:2002
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Xyrem
|
|
gptkbp:category
|
Schedule III controlled substance
|
|
gptkbp:clinical_trial
|
Phase IV
narcolepsy with cataplexy
narcolepsy without cataplexy
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
severe hepatic impairment
severe respiratory depression
history of succinic semialdehyde dehydrogenase deficiency
|
|
gptkbp:developed_by
|
Jazz Pharmaceuticals
|
|
gptkbp:dosage_form
|
gptkb:item
4.5 g per night
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
sodium salt
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sodium Oxybate
|
|
gptkbp:indication
|
cataplexy
excessive daytime sleepiness
|
|
gptkbp:ingredients
|
C4 H7 Na O3 S
|
|
gptkbp:interacts_with
|
gptkb:beer
CNS depressants
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_available_on
|
prescription medication
|
|
gptkbp:is_monitored_by
|
renal function
hepatic function
mental status
|
|
gptkbp:is_used_for
|
treatment of narcolepsy
|
|
gptkbp:lifespan
|
1 hour
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pharmacokinetics
|
linear pharmacokinetics
CNS depressant effects
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:products
|
gptkb:gamma-hydroxybutyrate
|
|
gptkbp:research_areas
|
neurology
pharmacology
sleep disorders
psychiatry
|
|
gptkbp:side_effect
|
gptkb:historical_event
anxiety
dizziness
headache
nausea
vomiting
confusion
seizures
insomnia
syncope
respiratory depression
nightmares
hypotension
bradycardia
|